Donor-derived Cell-free DNA: A Step Forward in the Quest for Transplant Truth.
Philip F Halloran, Katelynn S Madill-Thomsen
https://pubmed.ncbi.nlm.nih.gov/39883025/Actively Recruiting
Led by University of Alberta · Updated on 2026-10-06
300
Participants Needed
12
Research Sites
30 weeks
Total Duration
This research aims to understand the relationship between donor-derived cell-free DNA DD-cfDNA levels and HLA antibodies in blood samples from heart transplant recipients. It compares these blood test results with the Molecular Microscope Diagnostic System MMDx, a new diagnostic method that uses gene expression microarrays to assess heart transplant rejection and injury. The study focuses on improving the accuracy of rejection assessment beyond the current standard biopsy method, which has limitations due to variability in pathologist interpretations. Participants include heart transplant patients undergoing biopsies either for clinical reasons or as part of routine protocol monitoring. The study collects and compares data from 300 biopsies and 600 blood samples, using the Prospera test to measure DD-cfDNA levels and the MMDx system to analyze biopsy gene expression profiles. It also includes centralized testing of HLA antibodies in blood to assess donor-specific antibody status. Participants will be monitored through their standard care biopsies and blood sample collections. Researchers will evaluate the calibration of the Prospera test against MMDx findings for T cell-mediated rejection, antibody-mediated rejection, and heart injury over 18 months. Outcomes include reporting calibrated test results and assessing whether the Prospera blood test could potentially replace biopsy tests for rejection and follow-up. The study is ongoing until July 2028, with safety and diagnostic accuracy as key assessments.
CONDITIONS
Trifecta-Heart cfDNA-MMDx Study
K
Konrad Famulski, PhD
R
Robert Polakowski, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Alberta
Lead Sponsor
Natera, Inc.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 7 years
Participants undergo routine biopsies and blood sample collections as part of their standard care. These samples are analyzed using the Prospera blood test, MMDx gene expression test, and HLA antibody testing to assess transplant rejection and injury.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Philip F Halloran, Katelynn S Madill-Thomsen
https://pubmed.ncbi.nlm.nih.gov/39883025/Katelynn S Madill-Thomsen, Luis Guembes Hidalgo, Martina Mackova...
https://pubmed.ncbi.nlm.nih.gov/41241034/Katelynn S Madill-Thomsen, Luis G Hidalgo, Martina Mackova...
https://pubmed.ncbi.nlm.nih.gov/41833593/Philip F Halloran, Katelynn S Madill-Thomsen, D Giovanni Biagini...
https://pubmed.ncbi.nlm.nih.gov/42331120/Philip F Halloran, Katelynn S Madill-Thomsen
https://pubmed.ncbi.nlm.nih.gov/36508644/Katelynn S Madill-Thomsen, Philip F Halloran
https://pubmed.ncbi.nlm.nih.gov/38819301/Philip F Halloran, Jeff Reeve, Martina Mackova...
https://pubmed.ncbi.nlm.nih.gov/38538559/University of Alberta
Lead Sponsor
Natera, Inc.
Collaborating Sponsor